Neoprobe to Present at the Oppenheimer & Co. 22nd Annual Healthcare Conference
07 Dezember 2011 - 9:30PM
Business Wire
Neoprobe Corporation (NYSE Amex: NEOP) today announced that Dr.
Mark Pykett, President and Chief Executive Officer, will
participate at the Oppenheimer & Co. 22nd Annual Healthcare
Conference. Dr. Pykett will provide an update of the Company and
its development programs followed by a question and answer period
with institutional investors on December 13, 2011 at 10:50 AM EST
in New York City.
Investors and the public are invited to listen to a live webcast
of Dr. Pykett’s presentation at
http://www.veracast.com/webcasts/opco/healthcare2011/87109352.cfm.
Following the conference, the webcast will be archived for
approximately 30 days.
About Neoprobe
Neoprobe Corporation (NYSE Amex: NEOP) is a biomedical company
focused on the development and commercialization of precision
diagnostics and radiopharmaceutical agents. Neoprobe is actively
developing two radiopharmaceutical agent platforms – Lymphoseek®
and RIGScanTM CR – to help identify the sites and pathways of
undetected disease and enable better diagnostic accuracy, clinical
decision-making and ultimately patient care. Neoprobe’s strategy is
to deliver superior growth and shareholder return by bringing to
market novel radiopharmaceutical agents and advancing the Company’s
pipeline through selective acquisitions, global partnering and
commercialization efforts. For more information, please visit
www.neoprobe.com.
Neoprobe Corp. Common Stock (AMEX:NEOP)
Historical Stock Chart
Von Aug 2024 bis Sep 2024
Neoprobe Corp. Common Stock (AMEX:NEOP)
Historical Stock Chart
Von Sep 2023 bis Sep 2024
Echtzeit-Nachrichten über Neoprobe Corp. Common Stock (Amerikanische Börse): 0 Nachrichtenartikel
Weitere Neoprobe Corporation News-Artikel